Valuation: Reshape Lifesciences Inc

Market Cap 14.46M 12.7M 11.81M 10.84M 20.36M 1.39B 20.68M 140M 54.79M 685M 54.28M 53.11M 2.37B P/E 2026 *
-2.92x
P/E 2027 * -2.25x
Enterprise Value 14.46M 12.7M 11.81M 10.84M 20.36M 1.39B 20.68M 140M 54.79M 685M 54.28M 53.11M 2.37B EV / Sales 2026 *
96.4x
EV / Sales 2027 * 57.8x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 132K 123K 112K 211K 14.45M 214K 1.45M 568K 7.1M 563K 551K 24.55M 250K 220K 204K 187K 352K 24.08M 358K 2.42M 947K 11.84M 938K 918K 40.92M
Net income -4.89M -4.29M -3.99M -3.67M -6.89M -471M -6.99M -47.43M -18.53M -232M -18.36M -17.96M -800M -7.77M -6.82M -6.35M -5.82M -10.94M -748M -11.11M -75.35M -29.44M -368M -29.16M -28.54M -1.27B
Net Debt - -
Logo Reshape Lifesciences Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-